Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia
NCT ID: NCT01541943
Last Updated: 2015-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
356 participants
INTERVENTIONAL
2012-03-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
NCT04074551
Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
NCT04830449
Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia
NCT01442987
Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
NCT00157963
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
NCT04820907
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HL-040XC
Once daily, administered orally, 8 week
HL-040XC
Once daily, administered orally, 8 week
Atorvastatin
Once daily, administered orally, 8 week
Atorvastatin
Once daily, administered orally, 8 week
Losartan
Once daily, administered orally, 8 week
Losartan
Once daily, administered orally, 8 week
Placebo
Once daily, administered orally, 8 week
Placebo
Once daily, administered orally, 8 week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
Once daily, administered orally, 8 week
Losartan
Once daily, administered orally, 8 week
Placebo
Once daily, administered orally, 8 week
HL-040XC
Once daily, administered orally, 8 week
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of essential hypertension and hyperlipidemia
* Able to sign informed consent
Exclusion Criteria
* Has a history of hypersensitivity to Angiotensin Ⅱ receptor blocker or HMG-CoA reductase inhibitor or component of this drug
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HanAll BioPharma Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chang-Gyu Park, Medicine
Role: PRINCIPAL_INVESTIGATOR
Department of Cardiovascular, Korea University Guro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Guro Hospital
Seoul, Seoul, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HATLO11III_1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.